Title
CHOICE OF TRIGGER MEDICATION DOES NOT AFFECT OOCYTE MATURITY AT RETRIEVAL

Authors:
Carlos Hernandez-Nieto, MD1; Taraneh Nazem MD; Lucky Sekhon MD; Joseph A. Lee BA1; Dmitry Gounko MA1; Alan B. Copperman, MD1,2; Benjamin Sandler, MD1,2

Affiliations:
1. Reproductive Medicine Associates of New York, 635 Madison Ave 10th Floor New York, New York, United States, 10022
2. Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, Klingenstein Pavilion 1176 Fifth Avenue 9th Floor New York, New York, United States, 10029.

Objective:
Traditionally, final oocyte maturation with Human Chorionic Gonadotropin (hCG) was used as a standard component of IVF stimulation protocols. Currently, GnRH agonist and dual triggers have become the treatment of choice, as they have nearly eliminated the incidence of Ovarian Hyperstimulation Syndrome (OHSS). This study sought to compare whether choice of trigger medication had an effect on oocyte maturation rates.

Design:
Retrospective cohort analysis

Materials and Methods:
The study included patients undergoing IVF who were stimulated using the GnRH antagonist protocol between January 2002 and February 2017. Only patients classified as normal responders (AMH ≥1pmol/L, basal antral follicular count ≥10 and basal FSH ≤10IU/mL) were included. Cycles were segregated into 4 groups (Group A: GnRh agonist (leuprolide acetate 2mg); Group B: Dual trigger (leuprolide acetate 40IU + 1000IU p-hCH); Group C: Recombinant hCG (250 µg R-hCG); and Group D: purified hCG (10,000IU P-hCG)). Data was analyzed by ANOVA with Tukey’s studentized range test, with significance at p <0.05. Multivariate logistic regression analysis was performed to distinguish possible influence of clinical factors on the rate of oocyte maturation.
Results:
Of the 2,049 IVF cycles included, dual trigger was most commonly used (1172 cycles (57.3%)) followed by R-hCG:498 cycles (24.3%), GnRH agonist was administered least (178 cycles (8.6%)) (P-hCG: 201 cycles (9.8%))(Table 1).
Overall, 62.9% of oocytes reached the MII stage of development. When using P-hCG as a control group, significant differences between the MII rates per group were observed. (p <0.0001) (Figure 1). When adjusted for age, body mass index and the total number of eggs retrieved; no difference was observed between trigger method and the rate of MII oocyte formation (Table 2) (Figure 1).

Conclusions:
The GnRH agonist and dual triggers has proven to be a valuable option when treating patients who are at risk of OHSS and offers a greater margin of safety compared with the hCG trigger protocol. The study demonstrates no significant differences in the number of mature oocytes at retrieval when comparing different trigger strategies. Trigger medication choice can be based on patient-specific clinical characteristics that can reassure a decreased risk of OHSS without compromising oocyte maturity rates.

Support:
None.

Table 1.

<table>
<thead>
<tr>
<th>Variable</th>
<th>GnRH agonist N=178</th>
<th>Dual trigger N=1172</th>
<th>R-hCG N=498</th>
<th>P-hCG N=201</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Age</td>
<td>34.9 (±4.1)</td>
<td>35.8 (±3.8)</td>
<td>37.1 (±4.0)</td>
<td>36.9 (±4.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Mean BMI</td>
<td>23.4 (±4.4)</td>
<td>23.6 (±4.2)</td>
<td>23.1 (±3.8)</td>
<td>25.2 (±5.6)</td>
<td></td>
</tr>
<tr>
<td># Eggs retrieved</td>
<td>4254</td>
<td>22485</td>
<td>7210</td>
<td>2575</td>
<td></td>
</tr>
<tr>
<td>Mean Eggs retrieved</td>
<td>24.1 (±11.3)</td>
<td>19.4 (±8.8)</td>
<td>14.9 (±6.7)</td>
<td>13.2 (±6.1)</td>
<td></td>
</tr>
<tr>
<td># MII oocytes</td>
<td>2548</td>
<td>14302</td>
<td>4542</td>
<td>1613</td>
<td></td>
</tr>
<tr>
<td>Mean MII oocytes</td>
<td>14.4 (±12)</td>
<td>12.3 (±9.2)</td>
<td>9.4 (±6.4)</td>
<td>8.2 (±5.8)</td>
<td></td>
</tr>
<tr>
<td>% Maturity</td>
<td>59.8</td>
<td>63.6</td>
<td>62.9</td>
<td>62.4</td>
<td></td>
</tr>
</tbody>
</table>
Table 2.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Odds ratio estimates</th>
<th>95% Wald confidence limits</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (n= 2136)</td>
<td>1.122</td>
<td>1.07 – 1.17</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMI (n= 2136)</td>
<td>0.977</td>
<td>0.96 – 0.99</td>
<td>0.0124</td>
</tr>
<tr>
<td>Eggsretrieved (n=36524)</td>
<td>0.804</td>
<td>0.79 – 0.81</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Dual trigger vs P-hCG</td>
<td>0.968</td>
<td>0.74 – 1.24</td>
<td>NS</td>
</tr>
<tr>
<td>GnRH agonist vs P-hCG</td>
<td>1.19</td>
<td>0.82 – 1.74</td>
<td>NS</td>
</tr>
<tr>
<td>R-hCG vs P-hCG</td>
<td>0.967</td>
<td>0.733 – 1.274</td>
<td>NS</td>
</tr>
</tbody>
</table>
Figure 1.

Comparison of m2 with different trigger types:
- Dual
- Lupr
- hCG
- Ovidrel

Statistical Analysis:
- F: 28.99
- Prob > F: <.0001
Figure 2.

Odds Ratios with 95% Profile-Likelihood Confidence Limits

- TriggerType Dual vs hCG
- TriggerType Lupr vs hCG
- TriggerType ovidrel vs hCG

Variables:
- EggsRetrieved
- BMI
- OocyteAge

Odds Ratio

0.8 1.0 1.2 1.4 1.6 1.8